Literature DB >> 31493207

Evaluation of the clinical pharmacist role in improving clinical outcomes in patients with lower urinary tract symptoms due to benign prostatic hyperplasia.

Mera Ababneh1, Duaa Shamieh2, Saddam Al Demour3, Abeer Rababa'h2.   

Abstract

Background Lower urinary tract symptoms due to benign prostatic hyperplasia set restriction to patients' daily life activities and decrease their quality of life. Adherence to medications is considered a core element to improve patients' clinical outcomes. Objective To evaluate the role of clinical pharmacist in improving adherence to medication, reducing severity of symptoms, and improving quality of life in this group of patients. Setting The study was conducted in urology outpatients' clinics in Amman, Jordan. Methods This was a prospective randomized controlled trial, patients were randomly allocated into intervention group or control group. Patients in the intervention group were offered a pharmaceutical care service and patients in the control group received regular healthcare provided by urologist and then followed for 1 month. Main outcome measures Morisky Medication Adherence Score and International Prostate Symptom Score. Results Among 209 patients completed the study, 105 were in the intervention group and 104 in the control group. By the end of the study, 91.4% of the intervention group patients became adherent to their medication compared to 72.1% in the control group (p < 0.0001). At follow up, the severity of the symptoms to calculated score was lower in the intervention group (mean 15.6 ± 5.69) compared to control group (mean 13.9 ± 5.43) (p < 0.0001). The quality of life score were better in the intervention group compared to the control group at follow-up (p < 0.0001). Conclusion The current findings indicate that implementing clinical pharmacy services can positively increase the level of adherence to medications. This was accompanied by modest improvement in the severity of urinary symptoms in benign prostatic hyperplasia and in quality of life for patients. Hence, clinical pharmacy services could provide beneficence in outpatient setting.

Entities:  

Keywords:  Adherence; BPH; Clinical pharmacist; IPSS score; Jordan; LUTS; Pharmaceutical care

Mesh:

Year:  2019        PMID: 31493207     DOI: 10.1007/s11096-019-00896-2

Source DB:  PubMed          Journal:  Int J Clin Pharm


  20 in total

Review 1.  Interventions to improve adherence to medication in people with type 2 diabetes mellitus: a review of the literature on the role of pharmacists.

Authors:  A Lindenmeyer; H Hearnshaw; E Vermeire; P Van Royen; J Wens; Y Biot
Journal:  J Clin Pharm Ther       Date:  2006-10       Impact factor: 2.512

2.  Drug adherence and clinical outcomes for patients under pharmacological therapy for lower urinary tract symptoms related to benign prostatic hyperplasia: population-based cohort study.

Authors:  Luca Cindolo; Luisella Pirozzi; Caterina Fanizza; Marilena Romero; Andrea Tubaro; Riccardo Autorino; Cosimo De Nunzio; Luigi Schips
Journal:  Eur Urol       Date:  2014-11-20       Impact factor: 20.096

3.  Primary medication non-adherence: analysis of 195,930 electronic prescriptions.

Authors:  Michael A Fischer; Margaret R Stedman; Joyce Lii; Christine Vogeli; William H Shrank; M Alan Brookhart; Joel S Weissman
Journal:  J Gen Intern Med       Date:  2010-02-04       Impact factor: 5.128

Review 4.  Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms: What Is the Role and Significance of Inflammation?

Authors:  Granville L Lloyd; Jeffrey M Marks; William A Ricke
Journal:  Curr Urol Rep       Date:  2019-08-03       Impact factor: 3.092

5.  Adherence and Persistence Patterns in Medication Use Among Men With Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia.

Authors:  Emily Shortridge; Craig Donatucci; Prina Donga; Michael Marcus; Rolin L Wade
Journal:  Am J Mens Health       Date:  2016-06-22

Review 6.  Evidence-based guidelines in lower urinary tract symptoms secondary to benign prostatic hyperplasia and variation in care.

Authors:  Seth A Strope
Journal:  Curr Opin Urol       Date:  2018-05       Impact factor: 2.309

7.  A study on impact of clinical pharmacist interventions on medication adherence and quality of life in rural hypertensive patients.

Authors:  Kv Ramanath; Dbss Balaji; Ch Nagakishore; S Mahesh Kumar; M Bhanuprakash
Journal:  J Young Pharm       Date:  2012-04

Review 8.  Epidemiology of clinical benign prostatic hyperplasia.

Authors:  Kok Bin Lim
Journal:  Asian J Urol       Date:  2017-06-09

9.  The global burden of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A systematic review and meta-analysis.

Authors:  Shaun Wen Huey Lee; Esther Mei Ching Chan; Yin Key Lai
Journal:  Sci Rep       Date:  2017-08-11       Impact factor: 4.379

Review 10.  Patient centred care for the medical treatment of lower urinary tract symptoms in patients with benign prostatic obstruction: a key point to improve patients' care - a systematic review.

Authors:  Cosimo De Nunzio; Fabrizio Presicce; Riccardo Lombardo; Alberto Trucchi; Mariangela Bellangino; Andrea Tubaro; Egidio Moja
Journal:  BMC Urol       Date:  2018-06-26       Impact factor: 2.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.